For decades, people with fibromyalgia have often been told that their widespread pain, exhaustion, and "brain fog" were psychological, or that the condition was not quite real. A study published in Nature Medicine on 28 July 2026 offers the strongest evidence yet that the syndrome is rooted in the biology of the nervous system.

An international team analyzed genetic data from 2,563,755 adults, including 54,629 diagnosed with fibromyalgia, drawn from 11 cohorts in the United States, the United Kingdom, Finland, Estonia, Denmark, and Iceland. It is roughly a hundred times larger than the previous biggest genetics study of the condition. The researchers identified 26 regions of the genome where specific variants are more common in people with fibromyalgia than in those without it.

A signal in a Huntington's disease gene

The single strongest association lay inside HTT, the gene whose malfunction causes Huntington's disease, a rare and fatal neurodegenerative disorder. The fibromyalgia-linked variant is not the mutation that causes Huntington's. It is a small change in a different part of the gene that deletes one building block from the huntingtin protein, and carriers have about a 9 percent higher chance of developing fibromyalgia. The researchers checked directly and found that the Huntington's-causing mutation itself was not associated with fibromyalgia risk.

A second signal pointed near GPR52, a receptor that regulates how much huntingtin protein cells make. GPR52 is already being studied as a drug target for Huntington's disease, which raises the possibility that medicines developed for one condition could eventually be tested in the other. The authors describe this as a starting point for research, not a treatment.

Where the risk lives

The genetic signals did not scatter randomly across the body's tissues. When the team overlaid their results on maps of where genes are active, fibromyalgia heritability concentrated almost entirely in the brain and in nerve cells. Of the tissues showing a statistically significant signal, all five were brain regions. Of the enriched cell types, twelve of thirteen were neuronal, with the strongest signal in neurons of the dentate gyrus, a part of the hippocampus involved in giving context to sensory experiences, including pain.

Crucially, the analysis found no significant enrichment in immune cells or tissues. That pattern argues against fibromyalgia being primarily an autoimmune disease, a long-running hypothesis. The researchers caution that a peripheral immune or neuroimmune component could still exist and may have been hard to detect because most participants were of European ancestry and biobank volunteers tend to be healthier than the general population.

Shared roots with other conditions

The study also helps explain why fibromyalgia so often travels alongside other diagnoses. Fibromyalgia showed strong genetic overlap with several other conditions, with correlation coefficients above 0.7 for low back pain, post-traumatic stress disorder, and irritable bowel syndrome. The authors suggest that shared mechanisms within the nervous system may make some people vulnerable to a whole cluster of disorders at once.

For patients, the most immediate value may be legitimacy. "For decades, patients have been dismissed or told their pain is simply psychological," said Michael Wainberg, an investigator at the Lunenfeld-Tanenbaum Research Institute and a co-senior author. "Our findings confirm the condition has a clear biological basis."

What the study does not settle

The findings do not deliver a genetic test for fibromyalgia, and they do not point to an immediate new therapy. The individual variants each carry small effects, and the researchers emphasize that genetics is not the main determinant of who develops the syndrome. Even people carrying many risk variants likely need an additional trigger, such as a painful arthritic condition or other life events, before fibromyalgia emerges.

"Understanding how genes, environmental exposures, and life events jointly contribute to risk of fibromyalgia syndrome is critical," said Nasa Sinnott-Armstrong of Fred Hutch Cancer Center, another co-senior author. The study provides a biological framework and a list of concrete molecular targets. Turning that map into diagnosis or treatment is the next, and still open, question.

Sources